The latest update is out from ELEVAI Labs Inc. (ELAB).
Elevai Labs, Inc. has secured an exclusive license from MOA Life Plus Co., Ltd. to commercialize two innovative engineered probiotics aimed at treating muscle and obesity-related conditions. The deal involves an upfront payment and stock shares to MOA, plus royalties on net sales and milestone payments. Elevai filed provisional patents to protect the intellectual property of these potential treatments. Additionally, the company has formed two new subsidiaries to separate its skincare and biopharmaceutical ventures, positioning itself to focus on the development and commercialization of aesthetic drug candidates.
See more insights into ELAB stock on TipRanks’ Stock Analysis page.
